Welcome to the HCW Biologics Incorporated 2025 Annual Stockholder Meeting. I would like to note that during Dr. Wong's opening remarks, we may make forward-looking statements regarding future events which involve certain risks and uncertainties. Such statements are only predictions, and actual events or results could differ materially from those predictions due to a number of risks and uncertainties. I refer you to the documents the company files from time to time with the SEC, specifically the company's most recently filed annual report on Form 10-K, which was filed on March 28th, 2025, and its most recently filed quarterly report on Form 10-Q, which was filed on May 15th, 2025. These documents contain and identify important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. Dr. Wong, our Founder and Chief Executive Officer, will be making opening remarks. Dr. Wong. Good morning. This is Hing Wong, Founder and Chief Executive Officer of HCW Biologics. I also have the privilege of being the largest shareholder as well as a member of HCW Board of Directors. I would like to thank our stockholder for your continuous support. Since we met in March at the special meeting of stockholders, we complete several transactions which help us on our way to complete compliance with Nasdaq listing rules. We have required Nasdaq provides us with a formal compliance determination. This accomplishment was made possible by three major transactions we had completed since we last met. First, we raised $5.5 million to fund the development activity for our immunotherapeutics compounds. Second, we extinguished $6.6 million of debt by converting this debt to equity. Third, we formalized our relationship with WY Biotech after they accept our technology report. With this acceptance, the company would recognize $7 million of revenue in the second quarter of 2025. We will leverage the success we have made in securing financings to provide funding our ambitious clinical development plan. After many months of work to lay out multiple clinical sites at the leading institute, we are preparing to initiate a clinical trial to evaluate HCW9302 in an autoimmune disease in a multi-center trial. We are close to opening two major clinical sites in the next few weeks, and we anticipate dosing our first patient shortly after that. Our new round of financing will provide funding for critical study to continue developing new product candidates. We have construct using our second-generation drug discovery and development platform, we call the TRBC platform technology. We have so far advanced over 50 different compounds using this platform, and we are narrowing this down to most promising compounds. Our development plans including select a few molecules for internal development and identify those molecules that will be developed through business development programs. The TRBC platform technology is so versatile, it enable us to create multiple classes of immunotherapeutic compounds. The class 1 is the Multi-Functional Immune Cell simulator. One of these molecule is HCW11006 and was licensed to WY Biotech. We hope to be able to take advantage of our rights to get the market for the Americans after a phase I clinical trial is complete at no cost. This is a provision of our license. The class 2 is a second-generation immune checkpoint inhibitor, which focus on addressing the challenge of the checkpoint inhibitors such as KEYTRUDA. Finally, the class 3 is a Multi-Specific Targeting fusion and Enhanced Immune Cell engager. We have identified group of compounds in the class 3 as drug candidates to be developed through business development programs. The T-cell engager have revolutionized the immunotherapeutic approach against cancer, but they have difficulty and expensive clinical trial that require a well-capitalized big pharmaceutical company. Currently, the U.S. Food and Drug Administration have licensed 11 T-cell engager for hematologic and solid tumors. Now we are very excited that we report that our proprietary TRBC program discover and able to create potentially highly effective T-cell engagers against difficult and hard to treat solid tumors such as pancreatic cancer. I'm honored to be invited to present our innovative TRBC technology and the T-cell engager build based on this technology to a renowned group of experts who specialize in pancreatic cancer development and treatment as part of the Congregation Beth Israel organized by the HonorHealth in Scottsdale, Arizona on June 27, 2025. HonorHealth is a national center of excellence for the treatment of pancreatic cancer and a leading research institute in this disease. I would like to turn the meeting over to Scott Garrett, the Chairman of HCW Biologics and also of directors. Scott. Thank you, Hing. Welcome to the 2025 annual meeting of stockholders, which I will now call to order. Before further proceeding, let me introduce the non-employee directors who, in addition to myself, are with us today. Lisa Giles and Rick Greene. Gary Winer was unable to attend. Also in attendance today from HCW Biologics' executive staff are Hing C. Wong, CEO and Director, Rebecca Byam, Chief Financial Officer, Peter Rhode, Chief Scientific Officer, Lee Flowers, Senior Vice President, Business Development, Jack Egan, Vice President, Manufacturing and Quality Control, and Nicole Valdivieso, Vice President, Legal Affairs. Also present are representatives from our outside corporate counsel, Clark Hill, and from Crowe LLP, our independent public accounting firm. Rebecca Byam is acting as Inspector of Election for this meeting and has executed an Oath of Inspector of Election. Rules of procedure and questions. The rules of procedure are posted on the virtual annual meeting website. Please review them. In order to conduct an orderly meeting and give all eligible stockholders and proxy holders an opportunity to participate, we ask that you adhere to these rules at all times. An opportunity will be provided to present questions during the question and answer session of the annual meeting. However, please note that you may submit questions at any time during this virtual annual meeting in the space provided on the virtual annual meeting screen. Please follow the instructions provided on the virtual annual meeting screen to submit questions. We intend to make every effort to answer all questions. However, if multiple questions are submitted on the same topic, we will summarize and respond collectively. I will now turn the meeting over to Nicole Valdivieso, our Vice President, Legal Affairs, who is acting as Secretary for the meeting. Thank you, Scott. The board fixed April 22nd, 2025, as the record date for determining stockholders entitled to notice of and to vote at this meeting. An affidavit has been given to the Inspector of Elections attesting to the fact that the notice of meeting, the proxy statement, and the company's 2025 annual report to stockholders were mailed to all stockholders of record beginning April 28th, 2025. As the close of business on April 22nd, 2025, HCW Biologics had outstanding and entitled to vote 1,123,371 shares of common stock, each of which is entitled to one vote. Based on the tabulation of proxies already received from stockholders and to the best of our knowledge, there are present at this meeting a quorum for the transaction of business. The final report of the Inspector of Elections will include the votes, if any, of stockholders present and voting at the meeting. It is now 10:10, and the polls are open for voting. Any stockholders desiring to vote should do so at this time through the Internet using the virtual annual meeting website. If you have not yet voted or if you have previously voted and you now wish to revoke your proxy and change your vote, you may do so by clicking on the Vote Here button on the right-hand side of the screen. Any proxy may be revoked at any time before polling is closed by the electronic submission of a later-dated vote at the meeting, as I just described. We have two proposals from the company that stockholders are being asked to approve. The first item of business is to elect the Class I directors of HCW Biologics, Scott T. Garrett and Gary M. Winer. Second, to ratify the appointment of Crowe LLP as our independent registered public accounting firm for the year ending December 31st, 2025. Detailed information concerning these proposals is in the proxy statement sent or made available to HCW Biologics stockholders. We will now have a brief question and answer period on these proposals. If you have a question, please submit your question in the space provided on the virtual meeting screen and follow the instructions provided on the virtual meeting screen. The time allotted for questions and answers has expired. Is there anyone else who wishes to vote at the virtual meeting and has not yet submitted their vote? All votes should be submitted through the internet using the virtual meeting website at this time because votes cannot be accepted after the polls are closed, which will happen momentarily. All votes being submitted. It is now 10:12, and the polls are closed. Based on the information we have received from our Inspector of Elections, I will now announce the preliminary voting results for the meeting, which remain subject to the Inspector of Elections' final report. The nominee, Scott T. Garrett, has been elected. The nominee, Gary M. Winer, received a majority of withhold votes. Crowe LLP has been ratified as HCW Biologics' independent registered public accounting firm for the year ending December 31st, 2025. Final results of the vote will be recorded as stated in the minutes of this meeting and also filed with the Securities and Exchange Commission on Form 8-K within four business days. This concludes the formal business of the meeting. The 2025 annual meeting is now adjourned. I would like to thank you for attending today's virtual meeting. We will now entertain questions concerning matters that any of the stockholders of record may have. We will take stockholders' questions that are being entered now on the web portal. Please note we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. I will pause momentarily to wait for questions. I want to thank all of you for attending today's meeting and for the interest you've shown in the affairs of our company. We very much appreciate your attendance, and as always, thank you for your support. That concludes our meeting today. Thank you for joining. You may now disconnect.